Werner F. Blum, MD, PhD

Eli Lilly and Company
Lilly Diabetes
Ten Years After the United States Food and Drug Administration (US FDA) Approval of GH Treatment for Children with Idiopathic Short Stature (ISS): Who is Being Treated and What is the Response to Treatment?
Ten-Year Change in Quality of Life in Patients with Childhood and Adult Onset Growth Hormone Deficiency in the Hypopituitary Control and Complications Study (HypoCCS)
FP20-5 Development of Multiple Pituitary Hormone Deficiencies (MPHD) in Pediatric Patients Originally Diagnosed with Isolated GH Deficiency (IGHD) due to Organic Causes